Annovis Enterprise Value Trend from 2010 to 2022

ANVS -  USA Stock  

USD 9.15  0.50  5.18%

Annovis Bio Enterprise Value yearly trend continues to be relatively stable with very little volatility. Enterprise Value is likely to drop to about 89.9 M. During the period from 2010 to 2022, Annovis Bio Enterprise Value destribution of quarterly values had r-value of  0.62 from its regression line and mean deviation of  12,842,347. Annovis Bio Operating Expenses is relatively stable at the moment as compared to the past year. Annovis Bio reported last year Operating Expenses of 14.54 Million. As of 05/21/2022, Research and Development Expense is likely to grow to about 9.1 M, while Consolidated Income is likely to drop (14.9 M).
  
Refresh
Check Annovis Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Annovis main balance sheet or income statement drivers, such as Operating Expenses of 15.7 M, Research and Development Expense of 9.1 M or Selling General and Administrative Expense of 4.8 M, as well as many exotic indicators such as Book Value per Share of 6.3, Current Ratio of 32.94 or Debt to Equity Ratio of 0.0367. Annovis financial statements analysis is a perfect complement when working with Annovis Bio Valuation or Volatility modules. It can also supplement various Annovis Bio Technical models. Please continue to the analysis of Annovis Bio Correlation against competitors.

Annovis Bio Quarterly Enterprise Value

63.3 Million

Share
Enterprise Value (or EV) is usually referred to as Annovis Bio theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Annovis Bio debt, but would also pocket its cash. Enterprise Value is more accurate representation of Annovis Bio value than its market capitalization because it takes into account all of Annovis Bio existing debt.
All Fundamentals

About Annovis Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Annovis Bio income statement, its balance sheet, and the statement of cash flows. Annovis Bio investors use historical funamental indicators, such as Annovis Bio's Enterprise Value, to determine how well the company is positioned to perform in the future. Although Annovis Bio investors may use each financial statement separately, they are all related. The changes in Annovis Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Annovis Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Annovis Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Annovis Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Enterprise Value over EBIT(7.00) (7.55) 
Enterprise Value over EBITDA(6.55) (7.07) 
Enterprise Value95 M89.9 M
Tangible Asset Value46 M49.6 M
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The companys lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimers disease and Parkinsons disease, as well as is in clinical trials for Alzheimers disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Annovis Bio Investors Sentiment

The influence of Annovis Bio's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Annovis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Annovis Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Annovis Bio's short interest history, or implied volatility extrapolated from Annovis Bio options trading.

Current Sentiment - ANVS

Annovis Bio Investor Sentiment

Macroaxis portfolio users are unresponsive in their sentiment towards investing in Annovis Bio. What is your sentiment towards investing in Annovis Bio? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Trading with Annovis Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Annovis Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Annovis Bio will appreciate offsetting losses from the drop in the long position's value.

Annovis Bio Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Annovis Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Annovis Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Annovis Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Annovis Bio to buy it.
The correlation of Annovis Bio is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Annovis Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Annovis Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Annovis Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to the analysis of Annovis Bio Correlation against competitors. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.